{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:58:13Z","timestamp":1790290693327,"version":"4.1.0"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41569-025-01234-y","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T02:10:49Z","timestamp":1767319849000},"page":"392-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-0600","authenticated-orcid":false,"given":"Nicola C.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3551","authenticated-orcid":false,"given":"Davor","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N.","family":"Townend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1234_CR1","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"1234_CR2","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/ndt\/gfae048","volume":"39","author":"R Duff","year":"2024","unstructured":"Duff, R. et al. Global health inequalities of chronic kidney disease: a meta-analysis. Nephrol. Dial. Transplant. 39, 1692\u20131709 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1234_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali, C. et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc. Res. 119, 2017\u20132032 (2023).","journal-title":"Cardiovasc. Res."},{"key":"1234_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita, K. et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat. Rev. Nephrol. 18, 696\u2013707 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1234_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102615","volume":"72","author":"S Chadban","year":"2024","unstructured":"Chadban, S. et al. Projecting the economic burden of chronic kidney disease at the patient level (Inside CKD): a microsimulation modelling study. eClinicalMedicine 72, 102615 (2024).","journal-title":"eClinicalMedicine"},{"key":"1234_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/kisup.2015.2","volume":"5","author":"AJ Collins","year":"2015","unstructured":"Collins, A. J., Foley, R. N., Gilbertson, D. T. & Chen, S. C. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int. Suppl. 5, 2\u20137 (2015).","journal-title":"Kidney Int. Suppl."},{"key":"1234_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0140-6736(00)02456-9","volume":"356","author":"C Baigent","year":"2000","unstructured":"Baigent, C., Burbury, K. & Wheeler, D. Premature cardiovascular disease in chronic renal failure. Lancet 356, 147\u2013152 (2000).","journal-title":"Lancet"},{"key":"1234_CR8","unstructured":"Reports of medical cases, selected with a view of illustrating the symptoms and cure of diseases, by a reference to morbid anatomy. Med. Chir. Rev. 15, 289\u2013330 (1831)."},{"key":"1234_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/ndt\/5.1.39","volume":"5","author":"G Mall","year":"1990","unstructured":"Mall, G., Huther, W., Schneider, J., Lundin, P. & Ritz, E. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol. Dial. Transplant. 5, 39\u201344 (1990).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1234_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1523-1755.2005.00086.x","volume":"67","author":"J Aoki","year":"2005","unstructured":"Aoki, J. et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int. 67, 333\u2013340 (2005).","journal-title":"Kidney Int."},{"key":"1234_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.34067\/KID.0000000000000276","volume":"4","author":"G Narayanan","year":"2023","unstructured":"Narayanan, G. et al. Molecular phenotyping and mechanisms of myocardial fibrosis in advanced chronic kidney disease. Kidney360 4, 1562\u20131579 (2023).","journal-title":"Kidney360"},{"key":"1234_CR12","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.amjcard.2015.02.015","volume":"115","author":"NC Edwards","year":"2015","unstructured":"Edwards, N. C. et al. Diffuse interstitial fibrosis and myocardial dysfunction in early chronic kidney disease. Am. J. Cardiol. 115, 1311\u20131317 (2015).","journal-title":"Am. J. Cardiol."},{"key":"1234_CR13","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jcmg.2020.04.021","volume":"13","author":"MK Hayer","year":"2020","unstructured":"Hayer, M. K. et al. Defining myocardial abnormalities across the stages of chronic kidney disease: a cardiac magnetic resonance imaging study. JACC Cardiovasc. Imaging 13, 2357\u20132367 (2020).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"1234_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ki.1995.22","volume":"47","author":"RN Foley","year":"1995","unstructured":"Foley, R. N. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 47, 186\u2013192 (1995).","journal-title":"Kidney Int."},{"key":"1234_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/ndt\/11.7.1277","volume":"11","author":"PS Parfrey","year":"1996","unstructured":"Parfrey, P. S. et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol. Dial. Transplant. 11, 1277\u20131285 (1996).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1234_CR16","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1681\/ASN.2012020145","volume":"23","author":"M Park","year":"2012","unstructured":"Park, M. et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J. Am. Soc. Nephrol. 23, 1725\u20131734 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/01.HYP.35.2.580","volume":"35","author":"G Schillaci","year":"2000","unstructured":"Schillaci, G. et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 35, 580\u2013586 (2000).","journal-title":"Hypertension"},{"key":"1234_CR18","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","volume":"293","author":"MG Shlipak","year":"2005","unstructured":"Shlipak, M. G. et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293, 1737\u20131745 (2005).","journal-title":"JAMA"},{"key":"1234_CR19","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/sj.ki.5000249","volume":"69","author":"PB Mark","year":"2006","unstructured":"Mark, P. B. et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 69, 1839\u20131845 (2006).","journal-title":"Kidney Int."},{"key":"1234_CR20","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12968-016-0313-7","volume":"18","author":"KY Diao","year":"2016","unstructured":"Diao, K. Y. et al. Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J. Cardiovasc. Magn. Reson. 18, 92 (2016).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"1234_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.kint.2016.07.014","volume":"90","author":"MP Graham-Brown","year":"2016","unstructured":"Graham-Brown, M. P. et al. Novel cardiac nuclear magnetic resonance method for noninvasive assessment of myocardial fibrosis in hemodialysis patients. Kidney Int. 90, 835\u2013844 (2016).","journal-title":"Kidney Int."},{"key":"1234_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.kint.2016.06.014","volume":"90","author":"E Rutherford","year":"2016","unstructured":"Rutherford, E. et al. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney Int. 90, 845\u2013852 (2016).","journal-title":"Kidney Int."},{"key":"1234_CR23","doi-asserted-by":"publisher","first-page":"6878","DOI":"10.1007\/s00330-022-08839-8","volume":"32","author":"L Qin","year":"2022","unstructured":"Qin, L. et al. Value of native T1 mapping in the prediction of major adverse cardiovascular events in hemodialysis patients. Eur. Radiol. 32, 6878\u20136890 (2022).","journal-title":"Eur. Radiol."},{"key":"1234_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.109748","volume":"140","author":"MPM Graham-Brown","year":"2021","unstructured":"Graham-Brown, M. P. M. et al. Differences in native T1 and native T2 mapping between patients on hemodialysis and control subjects. Eur. J. Radiol. 140, 109748 (2021).","journal-title":"Eur. J. Radiol."},{"key":"1234_CR25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/hrt.2007.137539","volume":"94","author":"NC Edwards","year":"2008","unstructured":"Edwards, N. C., Ferro, C. J., Townend, J. N. & Steeds, R. P. Aortic distensibility and arterial\u2013ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart 94, 1038\u20131043 (2008).","journal-title":"Heart"},{"key":"1234_CR26","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.echo.2008.09.013","volume":"21","author":"NC Edwards","year":"2008","unstructured":"Edwards, N. C., Hirth, A., Ferro, C. J., Townend, J. N. & Steeds, R. P. Subclinical abnormalities of left ventricular myocardial deformation in early-stage chronic kidney disease: the precursor of uremic cardiomyopathy? J. Am. Soc. Echocardiogr. 21, 1293\u20131298 (2008).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"1234_CR27","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ndt\/gfu004","volume":"29","author":"R Krishnasamy","year":"2014","unstructured":"Krishnasamy, R. et al. The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. Nephrol. Dial. Transplant. 29, 1218\u20131225 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1234_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jjcc.2009.05.002","volume":"54","author":"T Otsuka","year":"2009","unstructured":"Otsuka, T., Suzuki, M., Yoshikawa, H. & Sugi, K. Left ventricular diastolic dysfunction in the early stage of chronic kidney disease. J. Cardiol. 54, 199\u2013204 (2009).","journal-title":"J. Cardiol."},{"key":"1234_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.echo.2021.12.003","volume":"35","author":"HY Liang","year":"2022","unstructured":"Liang, H. Y. et al. Associations between myocardial diastolic dysfunction and cardiovascular mortality in chronic kidney disease: a large single-center cohort study. J. Am. Soc. Echocardiogr. 35, 395\u2013407 (2022).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"1234_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeab037","volume":"1","author":"K Iwama","year":"2021","unstructured":"Iwama, K. et al. Chronic kidney disease and subclinical abnormalities of left heart mechanics in the community. Eur. Heart J. Open 1, oeab037 (2021).","journal-title":"Eur. Heart J. Open"},{"key":"1234_CR31","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/ndt\/gft482","volume":"29","author":"E Paoletti","year":"2014","unstructured":"Paoletti, E. & Zoccali, C. A look at the upper heart chamber: the left atrium in chronic kidney disease. Nephrol. Dial. Transplant. 29, 1847\u20131853 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1234_CR32","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1681\/ASN.2006101159","volume":"18","author":"A Kottgen","year":"2007","unstructured":"Kottgen, A. et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J. Am. Soc. Nephrol. 18, 1307\u20131315 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR33","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/ndt\/gfad011","volume":"38","author":"NC Edwards","year":"2023","unstructured":"Edwards, N. C., Price, A. M., Steeds, R. P., Ferro, C. J. & Townend, J. N. Management of heart failure in patients with kidney disease \u2014 updates from the 2021 ESC guidelines. Nephrol. Dial. Transplant. 38, 1798\u20131806 (2023).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1234_CR34","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/ckj\/sfac146","volume":"15","author":"PB Mark","year":"2022","unstructured":"Mark, P. B. et al. Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. Clin. Kidney J. 15, 2186\u20132199 (2022).","journal-title":"Clin. Kidney J."},{"key":"1234_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","volume":"5","author":"FA McAlister","year":"2012","unstructured":"McAlister, F. A. et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease\u2013Epidemiology Collaboration Group formula. Circ. Heart Fail. 5, 309\u2013314 (2012).","journal-title":"Circ. Heart Fail."},{"key":"1234_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100624","volume":"5","author":"AS Yu","year":"2023","unstructured":"Yu, A. S. et al. All-cause and cardiovascular-related mortality in CKD patients with and without heart failure: a population-based cohort study in Kaiser Permanente Southern California. Kidney Med. 5, 100624 (2023).","journal-title":"Kidney Med."},{"key":"1234_CR37","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1177\/2047487318777777","volume":"25","author":"DL Kirkman","year":"2018","unstructured":"Kirkman, D. L., Muth, B. J., Stock, J. M., Townsend, R. R. & Edwards, D. G. Cardiopulmonary exercise testing reveals subclinical abnormalities in chronic kidney disease. Eur. J. Prev. Cardiol. 25, 1717\u20131724 (2018).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1234_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCEP.110.957100","volume":"4","author":"U Baber","year":"2011","unstructured":"Baber, U. et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ. Arrhythm. Electrophysiol. 4, 26\u201332 (2011).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"1234_CR39","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","volume":"123","author":"A Alonso","year":"2011","unstructured":"Alonso, A. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123, 2946\u20132953 (2011).","journal-title":"Circulation"},{"key":"1234_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028496","volume":"12","author":"SM Kim","year":"2023","unstructured":"Kim, S. M. et al. Association of chronic kidney disease with atrial fibrillation in the general adult population: a nationwide population-based study. J. Am. Heart Assoc. 12, e028496 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ki.2009.144","volume":"76","author":"PG Korantzopoulos","year":"2009","unstructured":"Korantzopoulos, P. G. & Goudevenos, J. A. Atrial fibrillation in end-stage renal disease: an emerging problem. Kidney Int. 76, 247\u2013249 (2009).","journal-title":"Kidney Int."},{"key":"1234_CR42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.002097","volume":"1","author":"SE Nelson","year":"2012","unstructured":"Nelson, S. E., Shroff, G. R., Li, S. & Herzog, C. A. Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in Medicare patients. J. Am. Heart Assoc. 1, e002097 (2012).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.amjcard.2006.03.025","volume":"98","author":"I Goldenberg","year":"2006","unstructured":"Goldenberg, I. et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction. Am. J. Cardiol. 98, 485\u2013490 (2006).","journal-title":"Am. J. Cardiol."},{"key":"1234_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2013.12.009","volume":"64","author":"PH Pun","year":"2014","unstructured":"Pun, P. H. et al. Implantable cardioverter\u2013defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am. J. Kidney Dis. 64, 32\u201339 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"1234_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.121.056072","volume":"145","author":"A Yafasova","year":"2022","unstructured":"Yafasova, A. et al. Long-term follow-up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality). Circulation 145, 427\u2013436 (2022).","journal-title":"Circulation"},{"key":"1234_CR46","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1681\/ASN.2012010037","volume":"23","author":"IR Whitman","year":"2012","unstructured":"Whitman, I. R., Feldman, H. I. & Deo, R. CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J. Am. Soc. Nephrol. 23, 1929\u20131939 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR47","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.kint.2017.12.005","volume":"93","author":"PA Kalra","year":"2018","unstructured":"Kalra, P. A., Green, D. & Poulikakos, D. Arrhythmia in hemodialysis patients and its relation to sudden death. Kidney Int. 93, 781\u2013783 (2018).","journal-title":"Kidney Int."},{"key":"1234_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.kint.2021.10.025","volume":"101","author":"J Soppert","year":"2022","unstructured":"Soppert, J. et al. A systematic review and meta-analysis of murine models of uremic cardiomyopathy. Kidney Int. 101, 256\u2013273 (2022).","journal-title":"Kidney Int."},{"key":"1234_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.690517","volume":"8","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Uraemic cardiomyopathy in different mouse models. Front. Med. 8, 690517 (2021).","journal-title":"Front. Med."},{"key":"1234_CR50","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/hrt.2009.184879","volume":"96","author":"CD Chue","year":"2010","unstructured":"Chue, C. D., Townend, J. N., Steeds, R. P. & Ferro, C. J. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 96, 817\u2013823 (2010).","journal-title":"Heart"},{"key":"1234_CR51","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/heartjnl-2012-302818","volume":"99","author":"WE Moody","year":"2013","unstructured":"Moody, W. E., Edwards, N. C., Chue, C. D., Ferro, C. J. & Townend, J. N. Arterial disease in chronic kidney disease. Heart 99, 365\u2013372 (2013).","journal-title":"Heart"},{"key":"1234_CR52","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCRESAHA.123.321752","volume":"132","author":"C Baaten","year":"2023","unstructured":"Baaten, C., Vondenhoff, S. & Noels, H. Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease. Circ. Res. 132, 970\u2013992 (2023).","journal-title":"Circ. Res."},{"key":"1234_CR53","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/CIRCRESAHA.123.321760","volume":"132","author":"JD Hutcheson","year":"2023","unstructured":"Hutcheson, J. D. & Goettsch, C. Cardiovascular calcification heterogeneity in chronic kidney disease. Circ. Res. 132, 993\u20131012 (2023).","journal-title":"Circ. Res."},{"key":"1234_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011183","volume":"8","author":"SS Scholz","year":"2019","unstructured":"Scholz, S. S. et al. Effects of arteriovenous fistula on blood pressure in patients with end-stage renal disease: a systematic meta-analysis. J. Am. Heart Assoc. 8, e011183 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41371-022-00751-4","volume":"37","author":"JP Law","year":"2023","unstructured":"Law, J. P., Pickup, L., Pavlovic, D., Townend, J. N. & Ferro, C. J. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. J. Hum. Hypertens. 37, 1\u201319 (2023).","journal-title":"J. Hum. Hypertens."},{"key":"1234_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138461","volume":"10","author":"K Ioannou","year":"2015","unstructured":"Ioannou, K. et al. Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: a longitudinal study. PLoS ONE 10, e0138461 (2015).","journal-title":"PLoS ONE"},{"key":"1234_CR57","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/hc1102.105261","volume":"105","author":"C Zoccali","year":"2002","unstructured":"Zoccali, C. et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105, 1354\u20131359 (2002).","journal-title":"Circulation"},{"key":"1234_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1161\/01.HYP.0000022063.50739.60","volume":"40","author":"C Zoccali","year":"2002","unstructured":"Zoccali, C. et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40, 41\u201346 (2002).","journal-title":"Hypertension"},{"key":"1234_CR59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.122.011466","volume":"16","author":"BMN King","year":"2023","unstructured":"King, B. M. N. et al. Chronic kidney disease induces proarrhythmic remodeling. Circ. Arrhythm. Electrophysiol. 16, e011466 (2023).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"1234_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2017-000683","volume":"4","author":"R Malik","year":"2017","unstructured":"Malik, R., Waheed, S., Parashara, D., Perez, J. & Waheed, S. Association of QT interval with mortality by kidney function: results from the National Health and Nutrition Examination Survey (NHANES). Open Heart 4, e000683 (2017).","journal-title":"Open Heart"},{"key":"1234_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/srep40676","volume":"7","author":"AS Lee","year":"2017","unstructured":"Lee, A. S. et al. Electronegative LDL-mediated cardiac electrical remodeling in a rat model of chronic kidney disease. Sci. Rep. 7, 40676 (2017).","journal-title":"Sci. Rep."},{"key":"1234_CR62","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1681\/ASN.2013121343","volume":"25","author":"CH Hsueh","year":"2014","unstructured":"Hsueh, C. H. et al. Pathogenesis of arrhythmias in a model of CKD. J. Am. Soc. Nephrol. 25, 2812\u20132821 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR63","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.3390\/ijms24065373","volume":"24","author":"WB van Ham","year":"2023","unstructured":"van Ham, W. B. et al. Pro-arrhythmic potential of accumulated uremic toxins is mediated via vulnerability of action potential repolarization. Int. J. Mol. Sci. 24, 5373 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1234_CR64","doi-asserted-by":"publisher","first-page":"H2283","DOI":"10.1152\/ajpheart.00798.2020","volume":"320","author":"JM Graves","year":"2021","unstructured":"Graves, J. M. et al. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Am. J. Physiol. Heart Circ. Physiol. 320, H2283\u2013H2294 (2021).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1234_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00395-020-0810-6","volume":"115","author":"M Lindner","year":"2020","unstructured":"Lindner, M. et al. Fibroblast growth factor 23 decreases PDE4 expression in heart increasing the risk of cardiac arrhythmia; Klotho opposes these effects. Basic Res. Cardiol. 115, 51 (2020).","journal-title":"Basic Res. Cardiol."},{"key":"1234_CR66","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019338","volume":"10","author":"C Hall","year":"2021","unstructured":"Hall, C., Gehmlich, K., Denning, C. & Pavlovic, D. Complex relationship between cardiac fibroblasts and cardiomyocytes in health and disease. J. Am. Heart Assoc. 10, e019338 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/prd.12030","volume":"63","author":"B Hinz","year":"2013","unstructured":"Hinz, B. Matrix mechanics and regulation of the fibroblast phenotype. Periodontol. 2000 63, 14\u201328 (2013).","journal-title":"Periodontol. 2000"},{"key":"1234_CR68","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-\u03b2: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325\u2013338 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1234_CR69","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41569-021-00646-w","volume":"19","author":"NG Frangogiannis","year":"2022","unstructured":"Frangogiannis, N. G. Transforming growth factor-\u03b2 in myocardial disease. Nat. Rev. Cardiol. 19, 435\u2013455 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"1234_CR70","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cvr\/cvt074","volume":"99","author":"D Rahmutula","year":"2013","unstructured":"Rahmutula, D. et al. Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-\u03b21. Cardiovasc. Res. 99, 769\u2013779 (2013).","journal-title":"Cardiovasc. Res."},{"key":"1234_CR71","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/01.RES.86.5.571","volume":"86","author":"H Nakajima","year":"2000","unstructured":"Nakajima, H. et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-\u03b21 transgene in the heart. Circ. Res. 86, 571\u2013579 (2000).","journal-title":"Circ. Res."},{"key":"1234_CR72","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cvr\/cvu264","volume":"105","author":"JE Cartledge","year":"2015","unstructured":"Cartledge, J. E. et al. Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. Cardiovasc. Res. 105, 260\u2013270 (2015).","journal-title":"Cardiovasc. Res."},{"key":"1234_CR73","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00210-021-02130-1","volume":"394","author":"R Mohamed","year":"2021","unstructured":"Mohamed, R., Elshazly, S. M., Nafea, O. E. & Abd El Motteleb, D. M. Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4. Naunyn Schmiedebergs Arch. Pharmacol. 394, 2117\u20132128 (2021).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"1234_CR74","doi-asserted-by":"publisher","first-page":"H14","DOI":"10.1152\/ajpheart.2001.281.1.H14","volume":"281","author":"A Burger","year":"2001","unstructured":"Burger, A., Benicke, M., Deten, A. & Zimmer, H. G. Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 281, H14\u2013H21 (2001).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1234_CR75","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2741\/4405","volume":"21","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway. Front. Biosci. 21, 502\u2013513 (2016).","journal-title":"Front. Biosci."},{"key":"1234_CR76","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/eurheartj\/ehx366","volume":"39","author":"N Hermida","year":"2018","unstructured":"Hermida, N. et al. Cardiac myocyte \u03b23-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signaling. Eur. Heart J. 39, 888\u2013898 (2018).","journal-title":"Eur. Heart J."},{"key":"1234_CR77","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","volume":"68","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi, G., Perico, N., Macia, M. & Ruggenenti, P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 68, S57\u2013S65 (2005).","journal-title":"Kidney Int. Suppl."},{"key":"1234_CR78","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202500281R","volume":"39","author":"J Moellmann","year":"2025","unstructured":"Moellmann, J. et al. Development of a mouse model of uremic cardiomyopathy: investigating the impact of chronic kidney disease on cardiac function and signaling pathway. FASEB J. 39, e70639 (2025).","journal-title":"FASEB J."},{"key":"1234_CR79","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.cardiores.2004.04.030","volume":"63","author":"S Rosenkranz","year":"2004","unstructured":"Rosenkranz, S. TGF-\u03b21 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 63, 423\u2013432 (2004).","journal-title":"Cardiovasc. Res."},{"key":"1234_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96815-5","volume":"11","author":"ZZA Kovacs","year":"2021","unstructured":"Kovacs, Z. Z. A. et al. Comparison of the antiremodeling effects of losartan and mirabegron in a rat model of uremic cardiomyopathy. Sci. Rep. 11, 17495 (2021).","journal-title":"Sci. Rep."},{"key":"1234_CR81","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cardfail.2006.11.005","volume":"13","author":"Y Li","year":"2007","unstructured":"Li, Y. et al. Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure. J. Card. Fail. 13, 155\u2013162 (2007).","journal-title":"J. Card. Fail."},{"key":"1234_CR82","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","volume":"24","author":"Y Suematsu","year":"2018","unstructured":"Suematsu, Y. et al. LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease. J. Card. Fail. 24, 266\u2013275 (2018).","journal-title":"J. Card. Fail."},{"key":"1234_CR83","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","volume":"20","author":"S Johar","year":"2006","unstructured":"Johar, S., Cave, A. C., Narayanapanicker, A., Grieve, D. J. & Shah, A. M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 20, 1546\u20131548 (2006).","journal-title":"FASEB J."},{"key":"1234_CR84","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.lfs.2012.04.022","volume":"91","author":"K Kimura","year":"2012","unstructured":"Kimura, K., Ohkita, M., Koyama, M. & Matsumura, Y. Reduced NO production rapidly aggravates renal function through the NF-kB\/ET-1\/ETA receptor pathway in DOCA-salt-induced hypertensive rats. Life Sci. 91, 644\u2013650 (2012).","journal-title":"Life Sci."},{"key":"1234_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2019.102156","volume":"86","author":"D Pavlovic","year":"2020","unstructured":"Pavlovic, D. Endogenous cardiotonic steroids and cardiovascular disease, where to next? Cell Calcium 86, 102156 (2020).","journal-title":"Cell Calcium"},{"key":"1234_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000363301","volume":"128","author":"D Pavlovic","year":"2014","unstructured":"Pavlovic, D. The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin. Pract. 128, 11\u201321 (2014).","journal-title":"Nephron Clin. Pract."},{"key":"1234_CR87","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00424-008-0470-0","volume":"457","author":"Z Li","year":"2009","unstructured":"Li, Z. & Xie, Z. The Na\/K-ATPase\/Src complex and cardiotonic steroid-activated protein kinase cascades. Pflugers Arch. 457, 635\u2013644 (2009).","journal-title":"Pflugers Arch."},{"key":"1234_CR88","doi-asserted-by":"publisher","first-page":"27838","DOI":"10.1074\/jbc.M002950200","volume":"275","author":"J Liu","year":"2000","unstructured":"Liu, J. et al. Ouabain interaction with cardiac Na+\/K+-ATPase initiates signal cascades independent of changes in intracellular Na+ and Ca2+ concentrations. J. Biol. Chem. 275, 27838\u201327844 (2000).","journal-title":"J. Biol. Chem."},{"key":"1234_CR89","doi-asserted-by":"publisher","first-page":"17250","DOI":"10.1074\/jbc.M313239200","volume":"279","author":"H Wang","year":"2004","unstructured":"Wang, H. et al. Ouabain assembles signaling cascades through the caveolar Na+\/K+-ATPase. J. Biol. Chem. 279, 17250\u201317259 (2004).","journal-title":"J. Biol. Chem."},{"key":"1234_CR90","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1111\/j.1523-1755.2005.00283.x","volume":"67","author":"J Liu","year":"2005","unstructured":"Liu, J. et al. Ouabain-induced endocytosis of the plasmalemmal Na\/K-ATPase in LLC-PK1 cells requires caveolin-1. Kidney Int. 67, 1844\u20131854 (2005).","journal-title":"Kidney Int."},{"key":"1234_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1523-1755.2004.00723.x","volume":"66","author":"J Liu","year":"2004","unstructured":"Liu, J. et al. Ouabain induces endocytosis of plasmalemmal Na\/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. Kidney Int. 66, 227\u2013241 (2004).","journal-title":"Kidney Int."},{"key":"1234_CR92","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1046\/j.1523-1755.2002.00672.x","volume":"62","author":"J Liu","year":"2002","unstructured":"Liu, J. et al. Effects of cardiac glycosides on sodium pump expression and function in LLC-PK1 and MDCK cells. Kidney Int. 62, 2118\u20132125 (2002).","journal-title":"Kidney Int."},{"key":"1234_CR93","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1023\/A:1021114501561","volume":"242","author":"J Tian","year":"2003","unstructured":"Tian, J., Liu, J., Garlid, K. D., Shapiro, J. I. & Xie, Z. Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial KATP channels. Mol. Cell Biochem. 242, 181\u2013187 (2003).","journal-title":"Mol. Cell Biochem."},{"key":"1234_CR94","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/01.HYP.0000252409.36927.05","volume":"49","author":"J Elkareh","year":"2007","unstructured":"Elkareh, J. et al. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49, 215\u2013224 (2007).","journal-title":"Hypertension"},{"key":"1234_CR95","doi-asserted-by":"publisher","first-page":"L815","DOI":"10.1152\/ajplung.00322.2015","volume":"310","author":"J La","year":"2016","unstructured":"La, J. et al. Regulation of myofibroblast differentiation by cardiac glycosides. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L815\u2013L823 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1234_CR96","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/ijms21010263","volume":"21","author":"SF Rapa","year":"2019","unstructured":"Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A. & Marzocco, S. Inflammation and oxidative stress in chronic kidney disease \u2014 potential therapeutic role of minerals, vitamins and plant-derived metabolites. Int. J. Mol. Sci. 21, 263 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1234_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/srep23010","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGF\u03b21 and miR-29 pathways. Sci. Rep. 6, 23010 (2016).","journal-title":"Sci. Rep."},{"key":"1234_CR98","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","volume":"56","author":"GC Melendez","year":"2010","unstructured":"Melendez, G. C. et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56, 225\u2013231 (2010).","journal-title":"Hypertension"},{"key":"1234_CR99","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.ajpath.2023.09.011","volume":"193","author":"AA Widjaja","year":"2023","unstructured":"Widjaja, A. A. & Cook, S. A. The pathobiology of IL-11 in kidney disease: from epithelial cell to fibroblast and back again. Am. J. Pathol. 193, 1910\u20131913 (2023).","journal-title":"Am. J. Pathol."},{"key":"1234_CR100","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","volume":"552","author":"S Schafer","year":"2017","unstructured":"Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110\u2013115 (2017).","journal-title":"Nature"},{"key":"1234_CR101","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane, A. et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J. Am. Soc. Nephrol. 21, 1732\u20131744 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR102","first-page":"131","volume":"11","author":"L Ling","year":"2019","unstructured":"Ling, L., Yang, M., Ding, W. & Gu, Y. Ghrelin attenuates UUO-induced renal fibrosis via attenuation of Nlrp3 inflammasome and endoplasmic reticulum stress. Am. J. Transl. Res. 11, 131\u2013141 (2019).","journal-title":"Am. J. Transl. Res."},{"key":"1234_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167517","volume":"133","author":"J Song","year":"2023","unstructured":"Song, J. et al. Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation. J. Clin. Invest. 133, e167517 (2023).","journal-title":"J. Clin. Invest."},{"key":"1234_CR104","doi-asserted-by":"publisher","first-page":"699102","DOI":"10.3389\/fcvm.2021.699102","volume":"8","author":"MA Tanner","year":"2021","unstructured":"Tanner, M. A. & Grisanti, L. A. A dual role for death receptor 5 in regulating cardiac fibroblast function. Front. Cardiovasc. Med. 8, 699102 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"1234_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02864-1","volume":"11","author":"S Taguchi","year":"2021","unstructured":"Taguchi, S. et al. Effects of tumor necrosis factor-alpha inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy. Sci. Rep. 11, 23587 (2021).","journal-title":"Sci. Rep."},{"key":"1234_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-02383-3","volume":"15","author":"Y Xu","year":"2025","unstructured":"Xu, Y. et al. Neutrophil extracellular traps aggravate uremic cardiomyopathy by inducing myocardial fibroblast pyroptosis. Sci. Rep. 15, 17509 (2025).","journal-title":"Sci. Rep."},{"key":"1234_CR107","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00395-024-01056-y","volume":"119","author":"S Kundu","year":"2024","unstructured":"Kundu, S., Gairola, S., Verma, S., Mugale, M. N. & Sahu, B. D. Chronic kidney disease activates the HDAC6-inflammatory axis in the heart and contributes to myocardial remodeling in mice: inhibition of HDAC6 alleviates chronic kidney disease-induced myocardial remodeling. Basic Res. Cardiol. 119, 831\u2013852 (2024).","journal-title":"Basic Res. Cardiol."},{"key":"1234_CR108","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1126\/science.abn3100","volume":"377","author":"S Sano","year":"2022","unstructured":"Sano, S. et al. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science 377, 292\u2013297 (2022).","journal-title":"Science"},{"key":"1234_CR109","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/CIRCULATIONAHA.124.069139","volume":"150","author":"M Weyrich","year":"2024","unstructured":"Weyrich, M. et al. Loss of Y chromosome and cardiovascular events in chronic kidney disease. Circulation 150, 746\u2013757 (2024).","journal-title":"Circulation"},{"key":"1234_CR110","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/toxins13020142","volume":"13","author":"YJ Lim","year":"2021","unstructured":"Lim, Y. J., Sidor, N. A., Tonial, N. C., Che, A. & Urquhart, B. L. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: mechanisms and therapeutic targets. Toxins 13, 142 (2021).","journal-title":"Toxins"},{"key":"1234_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.toxlet.2015.01.021","volume":"234","author":"K Yang","year":"2015","unstructured":"Yang, K. et al. Indoxyl sulfate induces oxidative stress and hypertrophy in cardiomyocytes by inhibiting the AMPK\/UCP2 signaling pathway. Toxicol. Lett. 234, 110\u2013119 (2015).","journal-title":"Toxicol. Lett."},{"key":"1234_CR112","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/eurheartj\/ehp574","volume":"31","author":"S Lekawanvijit","year":"2010","unstructured":"Lekawanvijit, S. et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur. Heart J. 31, 1771\u20131779 (2010).","journal-title":"Eur. Heart J."},{"key":"1234_CR113","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12371","volume":"3","author":"I Rana","year":"2015","unstructured":"Rana, I. et al. Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. Physiol. Rep. 3, e12371 (2015).","journal-title":"Physiol. Rep."},{"key":"1234_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187459","volume":"12","author":"F Savira","year":"2017","unstructured":"Savira, F. et al. Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: implications for cardiorenal syndrome. PLoS ONE 12, e0187459 (2017).","journal-title":"PLoS ONE"},{"key":"1234_CR115","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacbts.2024.01.010","volume":"9","author":"SM Julovi","year":"2024","unstructured":"Julovi, S. M. et al. Thrombospondin-1 drives cardiac remodeling in chronic kidney disease. JACC Basic Transl. Sci. 9, 607\u2013627 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"1234_CR116","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.ajkd.2006.08.015","volume":"48","author":"E Dounousi","year":"2006","unstructured":"Dounousi, E. et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney Dis. 48, 752\u2013760 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"1234_CR117","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41581-023-00775-0","volume":"20","author":"S Kishi","year":"2024","unstructured":"Kishi, S., Nagasu, H., Kidokoro, K. & Kashihara, N. Oxidative stress and the role of redox signalling in chronic kidney disease. Nat. Rev. Nephrol. 20, 101\u2013119 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"1234_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1335094","volume":"14","author":"N Ren","year":"2023","unstructured":"Ren, N. et al. The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis. Front. Pharmacol. 14, 1335094 (2023).","journal-title":"Front. Pharmacol."},{"key":"1234_CR119","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe4932","volume":"14","author":"H Abe","year":"2021","unstructured":"Abe, H. et al. NF-kB activation in cardiac fibroblasts results in the recruitment of inflammatory Ly6Chi monocytes in pressure-overloaded hearts. Sci. Signal. 14, eabe4932 (2021).","journal-title":"Sci. Signal."},{"key":"1234_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103745","volume":"74","author":"C Yin","year":"2021","unstructured":"Yin, C. et al. Elevated Wnt2 and Wnt4 activate NF-kB signaling to promote cardiac fibrosis by cooperation of Fzd4\/2 and LRP6 following myocardial infarction. eBioMedicine 74, 103745 (2021).","journal-title":"eBioMedicine"},{"key":"1234_CR121","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.yexcr.2010.12.024","volume":"317","author":"M Sangeetha","year":"2011","unstructured":"Sangeetha, M., Pillai, M. S., Philip, L., Lakatta, E. G. & Shivakumar, K. NF-kB inhibition compromises cardiac fibroblast viability under hypoxia. Exp. Cell Res. 317, 899\u2013909 (2011).","journal-title":"Exp. Cell Res."},{"key":"1234_CR122","doi-asserted-by":"publisher","first-page":"F751","DOI":"10.1152\/ajprenal.00416.2023","volume":"326","author":"MJ Williams","year":"2024","unstructured":"Williams, M. J. et al. In chronic kidney disease altered cardiac metabolism precedes cardiac hypertrophy. Am. J. Physiol. Ren. Physiol. 326, F751\u2013F767 (2024).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1234_CR123","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.kint.2025.01.024","volume":"107","author":"MAA Fuchs","year":"2025","unstructured":"Fuchs, M. A. A. et al. Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease. Kidney Int. 107, 852\u2013868 (2025).","journal-title":"Kidney Int."},{"key":"1234_CR124","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016041","volume":"9","author":"JP Law","year":"2020","unstructured":"Law, J. P. et al. Clinical potential of targeting fibroblast growth factor-23 and alphaklotho in the treatment of uremic cardiomyopathy. J. Am. Heart Assoc. 9, e016041 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR125","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1681\/ASN.V4101814","volume":"4","author":"K Amann","year":"1994","unstructured":"Amann, K., Ritz, E., Wiest, G., Klaus, G. & Mall, G. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J. Am. Soc. Nephrol. 4, 1814\u20131819 (1994).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR126","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.nefro.2021.02.001","volume":"41","author":"L Martinez-Arias","year":"2021","unstructured":"Martinez-Arias, L. et al. Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure. Nefrologia 41, 640\u2013651 (2021).","journal-title":"Nefrologia"},{"key":"1234_CR127","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370\u20131378 (2011).","journal-title":"Kidney Int."},{"key":"1234_CR128","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Ren. Physiol. 299, F882\u2013F889 (2010).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1234_CR129","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121, 4393\u20134408 (2011).","journal-title":"J. Clin. Invest."},{"key":"1234_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02068-6","volume":"7","author":"A Grabner","year":"2017","unstructured":"Grabner, A. et al. FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible. Sci. Rep. 7, 1993 (2017).","journal-title":"Sci. Rep."},{"key":"1234_CR131","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.yjmcc.2019.11.149","volume":"138","author":"X Han","year":"2020","unstructured":"Han, X., Cai, C., Xiao, Z. & Quarles, L. D. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble klotho in mice. J. Mol. Cell Cardiol. 138, 66\u201374 (2020).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1234_CR132","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1210\/en.2018-00174","volume":"159","author":"ES Liu","year":"2018","unstructured":"Liu, E. S. et al. Increased circulating FGF23 does not lead to cardiac hypertrophy in the male hyp mouse model of XLH. Endocrinology 159, 2165\u20132172 (2018).","journal-title":"Endocrinology"},{"key":"1234_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10140-4","volume":"7","author":"S Slavic","year":"2017","unstructured":"Slavic, S. et al. Genetic ablation of Fgf23 or klotho does not modulate experimental heart hypertrophy induced by pressure overload. Sci. Rep. 7, 11298 (2017).","journal-title":"Sci. Rep."},{"key":"1234_CR134","doi-asserted-by":"publisher","first-page":"64649","DOI":"10.18632\/oncotarget.11623","volume":"7","author":"H Hao","year":"2016","unstructured":"Hao, H. et al. FGF23 promotes myocardial fibrosis in mice through activation of \u03b2-catenin. Oncotarget 7, 64649\u201364664 (2016).","journal-title":"Oncotarget"},{"key":"1234_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2022.100003","volume":"103","author":"T Saito","year":"2023","unstructured":"Saito, T. et al. Fibroblast growth factor 23 exacerbates cardiac fibrosis in deoxycorticosterone acetate\u2013salt mice with hypertension. Lab. Invest. 103, 100003 (2023).","journal-title":"Lab. Invest."},{"key":"1234_CR136","doi-asserted-by":"publisher","first-page":"ehae666.443","DOI":"10.1093\/eurheartj\/ehae666.443","volume":"45","author":"P Gao","year":"2024","unstructured":"Gao, P., Xie, B., Zhou, Z., Tse, G. & Liu, T. Elevation of circulating FGF23 in chronic kidney disease promotes atrial fibrosis through the AKT pathway. Eur. Heart J. 45, ehae666.443 (2024).","journal-title":"Eur. Heart J."},{"key":"1234_CR137","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1002\/ehf2.12816","volume":"7","author":"C Roy","year":"2020","unstructured":"Roy, C. et al. Fibroblast growth factor 23: a biomarker of fibrosis and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 7, 2494\u20132507 (2020).","journal-title":"ESC Heart Fail."},{"key":"1234_CR138","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/ki.2008.644","volume":"75","author":"CM Giachelli","year":"2009","unstructured":"Giachelli, C. M. The emerging role of phosphate in vascular calcification. Kidney Int. 75, 890\u2013897 (2009).","journal-title":"Kidney Int."},{"key":"1234_CR139","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.kint.2025.04.016","volume":"108","author":"M Fu","year":"2025","unstructured":"Fu, M. et al. The metabolite \u03b1-ketoglutarate inhibits vascular calcification partially through modulation of the TET2\/NLRP3 inflammasome signaling pathway. Kidney Int. 108, 233\u2013252 (2025).","journal-title":"Kidney Int."},{"key":"1234_CR140","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202403334R","volume":"39","author":"L Lu","year":"2025","unstructured":"Lu, L. et al. Sting facilitates vascular calcification via p-STAT1\/NLRP3 signal. FASEB J. 39, e70530 (2025).","journal-title":"FASEB J."},{"key":"1234_CR141","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3390\/jcm9082359","volume":"9","author":"S Roumeliotis","year":"2020","unstructured":"Roumeliotis, S., Mallamaci, F. & Zoccali, C. Endothelial dysfunction in chronic kidney disease, from biology to clinical outcomes: a 2020 update. J. Clin. Med. 9, 2359 (2020).","journal-title":"J. Clin. Med."},{"key":"1234_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23663-1","volume":"8","author":"HU Prommer","year":"2018","unstructured":"Prommer, H. U. et al. Chronic kidney disease induces a systemic microangiopathy, tissue hypoxia and dysfunctional angiogenesis. Sci. Rep. 8, 5317 (2018).","journal-title":"Sci. Rep."},{"key":"1234_CR143","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1042\/CS20200279","volume":"134","author":"U Querfeld","year":"2020","unstructured":"Querfeld, U., Mak, R. H. & Pries, A. R. Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity. Clin. Sci. 134, 1333\u20131356 (2020).","journal-title":"Clin. Sci."},{"key":"1234_CR144","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.037332","volume":"13","author":"DJ Campbell","year":"2024","unstructured":"Campbell, D. J., Francis, V. C. M., Young, G. R. & Woodford, N. W. F. Association of coronary microvascular rarefaction and myocardial fibrosis with coronary artery disease. J. Am. Heart Assoc. 13, e037332 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR145","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1373\/clinchem.2016.270520","volume":"63","author":"DA Duprez","year":"2017","unstructured":"Duprez, D. A. et al. Collagen turnover markers in relation to future cardiovascular and noncardiovascular disease: the multi-ethnic study of atherosclerosis. Clin. Chem. 63, 1237\u20131247 (2017).","journal-title":"Clin. Chem."},{"key":"1234_CR146","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00392-021-01898-9","volume":"111","author":"M Salib","year":"2022","unstructured":"Salib, M. et al. Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial. Clin. Res. Cardiol. 111, 614\u2013626 (2022).","journal-title":"Clin. Res. Cardiol."},{"key":"1234_CR147","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11255-019-02123-3","volume":"51","author":"T Zhang","year":"2019","unstructured":"Zhang, T., Cao, S., Yang, H. & Li, J. Prognostic impact of galectin-3 in chronic kidney disease patients: a systematic review and meta-analysis. Int. Urol. Nephrol. 51, 1005\u20131011 (2019).","journal-title":"Int. Urol. Nephrol."},{"key":"1234_CR148","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1007\/s11255-024-04107-4","volume":"56","author":"G Syn","year":"2024","unstructured":"Syn, G., Lee, Y. Q., Lim, Z. Y. & Chan, G. C. Galectin-3: action and clinical utility in chronic kidney disease. Int. Urol. Nephrol. 56, 3535\u20133543 (2024).","journal-title":"Int. Urol. Nephrol."},{"key":"1234_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30581","volume":"10","author":"C Chen","year":"2024","unstructured":"Chen, C. et al. NT-proBNP point-of-care testing for predicting mortality in end-stage renal disease: a survival analysis. Heliyon 10, e30581 (2024).","journal-title":"Heliyon"},{"key":"1234_CR150","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043014","volume":"104","author":"MY Jiang","year":"2025","unstructured":"Jiang, M. Y. & Wu, W. S. Association between high-sensitivity troponin and mortality risk in individuals with early kidney disease: a population-based cohort study. Medicine 104, e43014 (2025).","journal-title":"Medicine"},{"key":"1234_CR151","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12968-021-00762-z","volume":"23","author":"L Arcari","year":"2021","unstructured":"Arcari, L. et al. Cardiac biomarkers in chronic kidney disease are independently associated with myocardial edema and diffuse fibrosis by cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 23, 71 (2021).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"1234_CR152","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/genes13081390","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao, Y., Du, D., Chen, S., Chen, Z. & Zhao, J. New insights into the functions of micrornas in cardiac fibrosis: from mechanisms to therapeutic strategies. Genes 13, 1390 (2022).","journal-title":"Genes"},{"key":"1234_CR153","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/ijms24021792","volume":"24","author":"DD Motshwari","year":"2023","unstructured":"Motshwari, D. D. et al. MicroRNAs associated with chronic kidney disease in the general population and high-risk subgroups \u2014 a systematic review. Int. J. Mol. Sci. 24, 1792 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1234_CR154","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/ckj\/sfad017","volume":"16","author":"D Bolignano","year":"2023","unstructured":"Bolignano, D. et al. A small circulating miRNAs signature predicts mortality and adverse cardiovascular outcomes in chronic hemodialysis patients. Clin. Kidney J. 16, 868\u2013878 (2023).","journal-title":"Clin. Kidney J."},{"key":"1234_CR155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103079","volume":"9","author":"P Wen","year":"2014","unstructured":"Wen, P. et al. Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients. PLoS ONE 9, e103079 (2014).","journal-title":"PLoS ONE"},{"key":"1234_CR156","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/joneph\/19.1.77","volume":"19","author":"RM Fagugli","year":"2006","unstructured":"Fagugli, R. M. et al. Effects of short daily hemodialysis and extended standard hemodialysis on blood pressure and cardiac hypertrophy: a comparative study. J. Nephrol. 19, 77\u201383 (2006).","journal-title":"J. Nephrol."},{"key":"1234_CR157","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1097\/01.mat.0000249504.07371.5e","volume":"52","author":"J Ly","year":"2006","unstructured":"Ly, J. & Chan, C. T. Impact of augmenting dialysis frequency and duration on cardiovascular function. ASAIO J. 52, e11\u2013e14 (2006).","journal-title":"ASAIO J."},{"key":"1234_CR158","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.ajkd.2011.12.020","volume":"59","author":"P Susantitaphong","year":"2012","unstructured":"Susantitaphong, P., Koulouridis, I., Balk, E. M., Madias, N. E. & Jaber, B. L. Effect of frequent or extended hemodialysis on cardiovascular parameters: a meta-analysis. Am. J. Kidney Dis. 59, 689\u2013699 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"1234_CR159","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5414\/CNP66433","volume":"66","author":"T Weinreich","year":"2006","unstructured":"Weinreich, T., De los R\u00edos, T., Gauly, A. & Passlick-Deetjen, J. Effects of an increase in time vs. frequency on cardiovascular parameters in chronic hemodialysis patients. Clin. Nephrol. 66, 433\u2013439 (2006).","journal-title":"Clin. Nephrol."},{"key":"1234_CR160","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","volume":"292","author":"RB Devereux","year":"2004","unstructured":"Devereux, R. B. et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292, 2350\u20132356 (2004).","journal-title":"JAMA"},{"key":"1234_CR161","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004152","volume":"6","author":"MT L\u00f8nnebakken","year":"2017","unstructured":"L\u00f8nnebakken, M. T. et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J. Am. Heart Assoc. 6, e004152 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR162","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12882-022-02666-1","volume":"23","author":"KC Maki","year":"2022","unstructured":"Maki, K. C., Wilcox, M. L., Dicklin, M. R., Kakkar, R. & Davidson, M. H. Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 23, 34 (2022).","journal-title":"BMC Nephrol."},{"key":"1234_CR163","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","volume":"79","author":"F Buffolo","year":"2022","unstructured":"Buffolo, F., Tetti, M., Mulatero, P. & Monticone, S. Aldosterone as a mediator of cardiovascular damage. Hypertension 79, 1899\u20131911 (2022).","journal-title":"Hypertension"},{"key":"1234_CR164","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","volume":"54","author":"NC Edwards","year":"2009","unstructured":"Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J. & Townend, J. N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol. 54, 505\u2013512 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1234_CR165","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"1234_CR166","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"D Scott","year":"2024","unstructured":"Scott D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. New Engl. J. Med. 391, 1475\u20131485 (2024).","journal-title":"New Engl. J. Med."},{"key":"1234_CR167","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ehf2.14962","volume":"12","author":"G Filippatos","year":"2025","unstructured":"Filippatos, G. et al. Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes. ESC Heart Fail. 12, 185\u2013188 (2025).","journal-title":"ESC Heart Fail."},{"key":"1234_CR168","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2215\/CJN.01930221","volume":"16","author":"NC Edwards","year":"2021","unstructured":"Edwards, N. C. et al. Effects of spironolactone and chlorthalidone on cardiovascular structure and function in chronic kidney disease: a randomized, open-label trial. Clin. J. Am. Soc. Nephrol. 16, 1491\u20131501 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1234_CR169","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007180","volume":"13","author":"EL Fu","year":"2020","unstructured":"Fu, E. L. et al. Association between \u03b2-blocker use and mortality\/morbidity in patients with heart failure with reduced, midrange, and preserved ejection fraction and advanced chronic kidney disease. Circ. Heart Fail. 13, e007180 (2020).","journal-title":"Circ. Heart Fail."},{"key":"1234_CR170","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/ndt\/gft515","volume":"29","author":"R Agarwal","year":"2014","unstructured":"Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N. & Tegegne, G. G. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol. Dial. Transpl. 29, 672\u2013681 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1234_CR171","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/IJNRD.S414774","volume":"16","author":"I Haddiya","year":"2023","unstructured":"Haddiya, I. & Valoti, S. Current knowledge of beta-blockers in chronic hemodialysis patients. Int. J. Nephrol. Renovasc. Dis. 16, 223\u2013230 (2023).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"1234_CR172","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ijcard.2011.09.037","volume":"165","author":"Y Matsue","year":"2013","unstructured":"Matsue, Y. et al. Beta-blocker prevents sudden cardiac death in patients with hemodialysis. Int. J. Cardiol. 165, 519\u2013522 (2013).","journal-title":"Int. J. Cardiol."},{"key":"1234_CR173","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","volume":"355","author":"TB Dr\u00fceke","year":"2006","unstructured":"Dr\u00fceke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071\u20132084 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR174","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085\u20132098 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR175","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016041","volume":"9","author":"JP Law","year":"2020","unstructured":"Law, J. P. et al. Clinical potential of targeting fibroblast growth factor-23 and \u03b1klotho in the treatment of uremic cardiomyopathy. J. Am. Heart Assoc. 9, e016041 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR176","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","volume":"15","author":"X Wang","year":"2019","unstructured":"Wang, X. & Shapiro, J. I. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat. Rev. Nephrol. 15, 159\u2013175 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"1234_CR177","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/ehf2.13283","volume":"8","author":"LC Pickup","year":"2021","unstructured":"Pickup, L. C. et al. Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. ESC Heart Fail. 8, 2045\u20132057 (2021).","journal-title":"ESC Heart Fail."},{"key":"1234_CR178","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001647","volume":"10","author":"Z Tian","year":"2024","unstructured":"Tian, Z. et al. Left ventricular hypertrophy after renal transplantation: systematic review and meta-analysis. Transplant. Direct 10, e1647 (2024).","journal-title":"Transplant. Direct"},{"key":"1234_CR179","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR180","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR181","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031805","volume":"13","author":"R Kani","year":"2024","unstructured":"Kani, R. et al. Comparison of effectiveness among different sodium\u2013glucose cotransoporter-2 inhibitors according to underlying conditions: a network meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 13, e031805 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"1234_CR182","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31\u201339 (2019).","journal-title":"Lancet"},{"key":"1234_CR183","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jcmg.2020.07.025","volume":"14","author":"A Brown","year":"2021","unstructured":"Brown, A. et al. Dapagliflozin improves left ventricular myocardial longitudinal function in patients with type 2 diabetes. JACC Cardiovasc. Imaging 14, 503\u2013504 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"1234_CR184","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel, S. et al. Empagliflozin directly improves diastolic function in human heart failure. Eur. J. Heart Fail. 20, 1690\u20131700 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"1234_CR185","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","volume":"4","author":"KA Connelly","year":"2019","unstructured":"Connelly, K. A. et al. Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl. Sci. 4, 27\u201337 (2019).","journal-title":"JACC Basic Transl. Sci."},{"key":"1234_CR186","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","volume":"117","author":"YJ Chung","year":"2021","unstructured":"Chung, Y. J. et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc. Res. 117, 2794\u20132806 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1234_CR187","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/HJH.0000000000002776","volume":"39","author":"P Sarafidis","year":"2021","unstructured":"Sarafidis, P. et al. Sodium\u2013glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. J. Hypertens. 39, 1090\u20131097 (2021).","journal-title":"J. Hypertens."},{"key":"1234_CR188","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11906-024-01314-3","volume":"26","author":"R Siddiqui","year":"2024","unstructured":"Siddiqui, R., Obi, Y., Dossabhoy, N. R. & Shafi, T. Is there a role for SGLT2 inhibitors in patients with end-stage kidney disease? Curr. Hypertens. Rep. 26, 463\u2013474 (2024).","journal-title":"Curr. Hypertens. Rep."},{"key":"1234_CR189","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR190","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope, L. M. et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255\u20131266 (2010).","journal-title":"Lancet"},{"key":"1234_CR191","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR192","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cardfail.2023.10.221","volume":"30","author":"N Faraci","year":"2024","unstructured":"Faraci, N. et al. ACEi, ARB, or ARNI therapy reduces readmissions in patients with heart failure with reduced ejection fraction and chronic kidney disease stages IV or V. J. Card. Fail. 30, 207\u2013208 (2024).","journal-title":"J. Card. Fail."},{"key":"1234_CR193","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.mayocp.2022.06.007","volume":"98","author":"H-Y Chang","year":"2023","unstructured":"Chang, H.-Y. et al. Real-world experience of angiotensin receptor\u2013neprilysin inhibition in reduced ejection fraction heart failure patients with advanced kidney disease. Mayo Clin. Proc. 98, 88\u201399 (2023).","journal-title":"Mayo Clin. Proc."},{"key":"1234_CR194","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve, S. V. et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 13, 15\u201328 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1234_CR195","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1234_CR196","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/dom.15557","volume":"26","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Yang, D., Jia, Q., Yan, J. & An, F. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: an updated systematic review and meta-analysis. Diabetes Obes. Metab. 26, 2401\u20132411 (2024).","journal-title":"Diabetes Obes. Metab."},{"key":"1234_CR197","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2024.05","volume":"10","author":"A Shchendrygina","year":"2024","unstructured":"Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y. & Soloveva, A. Effects of glucagon-like peptide-1 receptor agonists on cardiac function, exercise capacity and quality of life. Card. Fail. Rev. 10, e10 (2024).","journal-title":"Card. Fail. Rev."},{"key":"1234_CR198","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463\u2013474 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"1234_CR199","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fphys.2019.01347","volume":"10","author":"D D\u2019Amario","year":"2019","unstructured":"D\u2019Amario, D. et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front. Physiol. 10, 1347 (2019).","journal-title":"Front. Physiol."},{"key":"1234_CR200","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1136\/heartjnl-2019-315138","volume":"105","author":"A Radhakrishnan","year":"2019","unstructured":"Radhakrishnan, A. et al. Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy? Heart 105, 1302\u20131309 (2019).","journal-title":"Heart"},{"key":"1234_CR201","doi-asserted-by":"publisher","DOI":"10.1111\/micc.12430","volume":"26","author":"HE Suhrs","year":"2019","unstructured":"Suhrs, H. E., Michelsen, M. M. & Prescott, E. Treatment strategies in coronary microvascular dysfunction: a systematic review of interventional studies. Microcirculation 26, e12430 (2019).","journal-title":"Microcirculation"},{"key":"1234_CR202","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1097\/HJH.0b013e32835f955c","volume":"31","author":"P Flevari","year":"2013","unstructured":"Flevari, P. et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J. Hypertens. 31, 1239\u20131244 (2013).","journal-title":"J. Hypertens."},{"key":"1234_CR203","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1681\/ASN.2016040453","volume":"28","author":"KL Nowak","year":"2017","unstructured":"Nowak, K. L. et al. IL-1 inhibition and vascular function in CKD. J. Am. Soc. Nephrol. 28, 971\u2013980 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1234_CR204","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/eurheartj\/ehae722","volume":"46","author":"A Kel","year":"2025","unstructured":"Kel, A., Thum, T. & Kunduzova, O. Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy. Eur. Heart J. 46, 354\u2013358 (2025).","journal-title":"Eur. Heart J."},{"key":"1234_CR205","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39369-y","volume":"13","author":"C Hall","year":"2023","unstructured":"Hall, C. et al. Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype. Sci. Rep. 13, 12137 (2023).","journal-title":"Sci. Rep."},{"key":"1234_CR206","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","volume":"26","author":"J Bauersachs","year":"2024","unstructured":"Bauersachs, J. et al. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-revert trial. Eur. J. Heart Fail. 26, 674\u2013682 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"1234_CR207","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","volume":"42","author":"S Batkai","year":"2020","unstructured":"Batkai, S. et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur. Heart J. 42, 192\u2013201 (2020).","journal-title":"Eur. Heart J."},{"key":"1234_CR208","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel, J. et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur. Heart J. 42, 178\u2013188 (2021).","journal-title":"Eur. Heart J."},{"key":"1234_CR209","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1016\/j.jacc.2021.04.028","volume":"77","author":"R Hinkel","year":"2021","unstructured":"Hinkel, R. et al. AntimiR-132 attenuates myocardial hypertrophy in an animal model of percutaneous aortic constriction. J. Am. Coll. Cardiol. 77, 2923\u20132935 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1234_CR210","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2090","volume":"3","author":"A Ucar","year":"2012","unstructured":"Ucar, A. et al. The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 3, 1078 (2012).","journal-title":"Nat. Commun."},{"key":"1234_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104694","volume":"155","author":"A Aimo","year":"2020","unstructured":"Aimo, A. et al. Pirfenidone is a cardioprotective drug: mechanisms of action and preclinical evidence. Pharmacol. Res. 155, 104694 (2020).","journal-title":"Pharmacol. Res."},{"key":"1234_CR212","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41591-021-01452-0","volume":"27","author":"GA Lewis","year":"2021","unstructured":"Lewis, G. A. et al. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat. Med. 27, 1477\u20131482 (2021).","journal-title":"Nat. Med."},{"key":"1234_CR213","doi-asserted-by":"publisher","unstructured":"Lok, C. E. et al. Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2513032 (2025).","DOI":"10.1056\/NEJMoa2513032"},{"key":"1234_CR214","doi-asserted-by":"publisher","first-page":"802306","DOI":"10.3389\/fcvm.2021.802306","volume":"8","author":"J Liao","year":"2021","unstructured":"Liao, J., Xiong, Q., Yin, Y., Ling, Z. & Chen, S. The effects of fish oil on cardiovascular diseases: systematical evaluation and recent advance. Front. Cardiovasc. Med. 8, 802306 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"1234_CR215","doi-asserted-by":"publisher","first-page":"J3","DOI":"10.1093\/eurheartj\/suaa115","volume":"22","author":"TD O\u2019Connell","year":"2020","unstructured":"O\u2019Connell, T. D., Mason, R. P., Budoff, M. J., Navar, A. M. & Shearer, G. C. Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites. Eur. Heart. J. Suppl. 22, J3\u2013J20 (2020).","journal-title":"Eur. Heart. J. Suppl."},{"key":"1234_CR216","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","volume":"387","author":"X Xie","year":"2016","unstructured":"Xie, X. et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387, 435\u2013443 (2016).","journal-title":"Lancet"},{"key":"1234_CR217","first-page":"100725","volume":"33","author":"JL Benham","year":"2021","unstructured":"Benham, J. L. et al. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int. J. Cardiol. Heart Vasc. 33, 100725 (2021).","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"1234_CR218","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.691907","volume":"8","author":"GM Gager","year":"2021","unstructured":"Gager, G. M. et al. Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis. Front. Cardiovasc. Med. 8, 691907 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"1234_CR219","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman, M. S. et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 12, 447\u2013461 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1234_CR220","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70065","volume":"48","author":"M Ahmed","year":"2025","unstructured":"Ahmed, M. et al. Cardiovascular efficacy and safety of finerenone: a meta-analysis of randomized controlled trials. Clin. Cardiol. 48, e70065 (2025).","journal-title":"Clin. Cardiol."},{"key":"1234_CR221","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/joim.20050","volume":"297","author":"F Zannad","year":"2025","unstructured":"Zannad, F., McGuire, D. K. & Ortiz, A. Treatment strategies to reduce cardiovascular risk in persons with chronic kidney disease and type 2 diabetes. J. Intern. Med. 297, 460\u2013478 (2025).","journal-title":"J. Intern. Med."},{"key":"1234_CR222","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2009.219","volume":"76","author":"PH Pun","year":"2009","unstructured":"Pun, P. H. et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int. 76, 652\u2013658 (2009).","journal-title":"Kidney Int."},{"key":"1234_CR223","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/ki.2014.393","volume":"87","author":"JN Liao","year":"2015","unstructured":"Liao, J. N. et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 87, 1209\u20131215 (2015).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01234-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01234-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:03:38Z","timestamp":1779278618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01234-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":223,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01234-y","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"12 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}